How does diabetes affect the liver? Type 2 diabetes is closely linked with metabolic dysfunction-associated steatotic liver disease (MASLD), and the relationship goes both ways: each condition increases the risk of the other, according to the CDC. In some people, extra liver fat leads to inflammation and scarring, but having diabetes does not by itself mean someone has liver disease. Screening and an individualized care plan matter even when someone feels well.
Key takeaways
- MASLD and metabolic dysfunction-associated steatohepatitis (MASH), formerly NAFLD/NASH, describe related but different liver conditions; MASH includes inflammation and liver-cell injury.
- The CDC describes a two-way relationship between type 2 diabetes and MASLD. Neither condition proves that one caused the other in an individual.
- The American Diabetes Association (ADA) recommends assessing liver-scarring risk in adults with type 2 diabetes or prediabetes, particularly those with obesity or other cardiometabolic risk factors, even with normal liver enzymes.
- Liver health belongs in a broader care plan that addresses cardiovascular risk, nutrition, activity, and clinician-led follow-up, not a self-directed supplement routine.
How Does Diabetes Affect the Liver? The Quick Answer
Type 2 diabetes is associated with a greater risk of fatty liver disease, including MASLD and its inflammatory form, MASH. The ADA's Standards of Care in Diabetes—2026 estimate that MASLD affects more than 70% of U.S. adults with type 2 diabetes. That is a group estimate, not a diagnosis or prediction for one person. A care team assesses liver-scarring risk alongside diabetes and cardiovascular health, rather than relying only on symptoms or routine liver enzymes.
The connection deserves attention without assuming that everyone has the same disease or outlook. Finding fat, identifying inflammation, and assessing scarring are different clinical questions. A report that mentions one does not automatically answer the others.
What Is MASLD, and How Is It Different From MASH?
The language around fatty liver disease has changed. A multisociety consensus led by Rinella and colleagues introduced names that describe metabolic risk more directly. Older records and some government information pages still use earlier terms, so a clinician may need to explain how a past report relates to current terminology.
MASLD describes liver fat together with a cardiometabolic risk factor. MASH describes the inflammatory form, with liver-cell injury as well as fat. The word "fatty" alone does not tell a reader whether inflammation or scarring is present.
| Term | Plain-language meaning | A question for the care team |
|---|---|---|
| SLD: steatotic liver disease | The umbrella term for conditions involving liver fat. | Which cause of liver fat is being considered? |
| MASLD: metabolic dysfunction-associated steatotic liver disease | Liver fat together with a cardiometabolic risk factor. | How does my metabolic health fit into the assessment? |
| MASH: metabolic dysfunction-associated steatohepatitis | Fat with inflammation and liver-cell injury. | What evidence is needed to assess inflammation and scarring? |
| MetALD | A separate category for MASLD when alcohol exposure exceeds the MASLD definition. | What history should I share so the clinician can assess the cause? |
This glossary is a discussion guide, not a self-diagnosis tool. These labels cannot be assigned from a symptom list, body size, or a glucose reading. Ask your clinician to explain the term in your records and what remains uncertain.
Does Diabetes Cause Fatty Liver, and Can Fatty Liver Cause Diabetes?
The clearest answer is that type 2 diabetes and MASLD have a two-way association. The CDC says having either condition increases the risk of the other. The ADA also identifies people with MASLD as being at greater risk of developing type 2 diabetes. This supports coordinated care, but it does not establish which condition came first or why either developed in a particular person.
Insulin resistance is an important part of this discussion. The ADA links liver risk with insulin resistance and other cardiometabolic factors. Our overview of insulin resistance and metabolic health gives context for that shared risk without turning it into an explanation of any individual's results.
"Does diabetes cause fatty liver?" can sound like a simple cause-and-effect question. In practice, clinicians consider a wider picture, including metabolic risk, genetic predisposition, environmental factors, and other possible causes of liver disease. Having diabetes is a reason to assess risk, not a reason to skip that evaluation.
Similarly, "can fatty liver cause diabetes?" should not be read as a certainty that diabetes will follow. Increased risk is not the same as an inevitable outcome. A clinician can decide how glucose assessment and liver follow-up fit together.
Who Has Higher Liver Risk, Including People at a Normal Weight?
The ADA identifies central obesity, other cardiometabolic risk factors, insulin resistance, and persistently elevated liver enzymes as reasons for greater concern. Age also matters: the ADA describes higher risk among people older than 50. These are patterns seen in groups, not a checklist that establishes disease in someone who matches them.
Body size does not settle the question. The ADA notes that steatohepatitis and cirrhosis can occur in lean people with diabetes, with genetic predisposition, insulin resistance, and environmental factors thought to contribute. AASLD practice guidance likewise recognizes fatty liver in people who are not overweight.
That means a person at a normal weight should not dismiss liver-health questions simply because a public-health message focuses on obesity. Our guide to diabetes in people who are not overweight explores the broader issue without making appearance a screening test.
Type of diabetes matters too. The ADA estimates MASLD prevalence at about 20% in people with type 1 diabetes. That group estimate does not mean the same screening approach applies to every person with every type of diabetes. Ask your diabetes clinician how your history and additional risk factors affect the assessment.
Why Does Liver Scarring Matter Beyond Liver Fat?
Fibrosis means scarring. It is a different issue from the presence of fat, and assessing it is central to deciding who may need more evaluation. The ADA's screening recommendation focuses on the risk of MASH-related cirrhosis rather than simply finding liver fat.
The ADA's statement on liver disease in diabetes explains that MASH raises the risk of cirrhosis and liver cancer. These are potential risks, not a statement that everyone with MASLD will develop them. A clinician needs the full assessment before discussing the significance of a finding or a person's outlook.
Cardiovascular health also belongs in this conversation. The ADA reports that cardiovascular disease is the leading cause of death among people with both type 2 diabetes and MASLD. That is a finding about a population, not a personal forecast. It is a reason to avoid viewing liver care as separate from the rest of diabetes care.
The broader guide to diabetes and stroke risk can help frame cardiovascular questions for your clinician. A liver finding should prompt coordinated discussion, not the assumption that focusing on the liver replaces attention to other health risks.
How Can a Care Team Assess Risk When Someone Feels Well?
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes fatty liver disease as usually silent, with few or no symptoms, even when it progresses to cirrhosis. Feeling well is therefore not enough to rule it out. Fatigue or upper-right abdominal discomfort can occur, but neither confirms a liver condition.
The ADA's Standards of Care in Diabetes—2026 recommend assessing risk of MASH-related cirrhosis in adults with type 2 diabetes or prediabetes, particularly with obesity, other cardiometabolic risk factors, or established cardiovascular disease. The recommendation applies even if liver enzymes are normal. Waiting for symptoms or an enzyme result to become abnormal can miss people who need assessment.
FIB-4 is a calculated score that uses age, liver blood tests called AST and ALT, and platelets. Clinicians use it to help decide whether further assessment of fibrosis risk is needed. It is not a standalone diagnosis, and a reader should not interpret a personal result from an article.
Follow-up may include elastography, which measures liver stiffness, another blood test, or referral to a gastroenterologist or hepatologist. NIDDK explains that routine imaging can show fat but cannot show inflammation or fibrosis. Different tests answer different questions, so ask what a proposed test is intended to clarify.
For urgent changes, MedlinePlus advises emergency help for new or rapidly worsening yellowing of the skin or eyes, confusion or changed alertness, bleeding, or new or suddenly worse abdominal swelling; NIDDK says vomiting blood or black or bloody stools require hospital care right away. Seek emergency care rather than waiting for a routine liver appointment.
What Can Lifestyle Support and Clinical Treatment Contribute?
The ADA recommends an interprofessional approach to lifestyle changes for adults with type 2 diabetes or prediabetes and MASLD, particularly with overweight or obesity. This ideally includes a structured nutrition plan and physical activity program. The purpose is individualized support, not a universal food rule or a promise of a particular result.
The ADA identifies the Mediterranean eating pattern as having the best evidence for liver and cardiometabolic health. A care-team conversation can focus on meals built around vegetables, legumes, and whole grains in a way that fits an existing diabetes plan. Ask a dietitian how to adapt the pattern to preferences, access to food, and other health needs.
Both aerobic and resistance activity are supported in the ADA's guidance. NIDDK notes that physical activity can be beneficial even without weight loss. Discuss what is safe and sustainable with your care team rather than judging progress only by the scale.
If weight change is part of care, the plan should be individualized and gradual. NIDDK warns that rapid weight loss and malnutrition can worsen liver disease. Research findings about improvement in groups are not personal targets, and no article can promise how quickly fat, inflammation, or scarring will change.
The CDC advises limiting alcohol; discuss it with your clinician and read our guide to alcohol and diabetes for that separate conversation.
According to NIH LiverTox, herbal and dietary supplements, including products marketed for liver health, can themselves injure the liver and should be reviewed with a pharmacist or clinician. A product's marketing is not evidence of safety or an alternative to assessment.
The ADA also describes certain glucose-lowering and weight-management medicines, a liver-specific medicine considered with a specialist, and metabolic surgery as options for some adults. Decisions are individualized with an interprofessional team. For medicine questions, our guide to GLP-1 medicines and fatty liver provides context to discuss with your prescriber, not instructions to change treatment.
What Does the Rest of This Liver Guide Cover?
The companion pages separate questions that often get bundled together. Choose the one that fits your current conversation, while remembering that none can identify the cause of a symptom or interpret a personal test.
- Understanding possible fatty liver symptoms explains why the disease can be silent, why fatigue and discomfort are nonspecific, and which warning signs require urgent care.
- What improvement in fatty liver can mean distinguishes changes in fat, inflammation, and scarring, with emphasis on individual variation rather than a guaranteed timeline.
- Discussing liver assessment with a diabetes clinician explains how screening and follow-up tests fit together and why normal enzymes do not end the conversation.
Before a visit, gather prior reports and write down the question you most want answered. The diabetes appointment preparation checklist can help organize records and a complete medicine-and-supplement list. Ask who coordinates the diabetes and liver plans if several clinicians are involved.
Frequently Asked Questions
How does diabetes affect the liver?
Type 2 diabetes is associated with a greater risk of MASLD, a condition involving liver fat and metabolic risk. Some people also have inflammation, liver-cell injury, or scarring. The ADA recommends assessing scarring risk even with normal liver enzymes. Diabetes alone does not establish a liver diagnosis or determine an individual's outlook.
Does diabetes cause fatty liver in everyone?
No. The CDC describes type 2 diabetes and MASLD as conditions that increase the risk of each other, not as an inevitable sequence. A clinician considers metabolic risk and other possible causes of liver disease. Having diabetes is a reason to discuss assessment, not proof that liver fat or scarring is present.
Can fatty liver cause diabetes?
People with MASLD have a greater risk of developing type 2 diabetes, according to the ADA and CDC. That association does not prove that fatty liver caused one person's diabetes or that everyone with MASLD will develop it. A clinician can decide how glucose assessment and liver follow-up fit together.
What is MASLD?
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It describes liver fat together with a cardiometabolic risk factor. MASH is its inflammatory form, involving liver-cell injury as well as fat. A clinician determines the appropriate diagnosis; the terms cannot be assigned from symptoms, body size, or a glucose reading alone.
Can people at a normal weight have fatty liver disease?
Yes. The ADA and AASLD recognize fatty liver disease in people who are not overweight, and the ADA notes that steatohepatitis and cirrhosis can occur in lean people with diabetes. Body size does not establish or rule out the condition. Ask your clinician how your complete history affects the need for assessment.
Do normal liver enzymes rule out liver disease?
No. The ADA recommends assessing risk of MASH-related cirrhosis in adults with type 2 diabetes or prediabetes even when liver enzymes are normal. Clinicians may use a calculated fibrosis score and decide whether further tests are appropriate. An enzyme result alone cannot establish the presence or absence of inflammation or scarring.
References
- American Diabetes Association Professional Practice Committee. "4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl. 1):S61–S88. Accessed October 2026.
- Centers for Disease Control and Prevention (CDC). "Type 2 Diabetes and Your Liver." Accessed October 2026.
- Rinella ME, et al. "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Hepatology. 2023;78(6):1966–1986.
- Rinella ME, et al. "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease." Hepatology. 2023;77(5):1797–1835.
- American Diabetes Association. "American Diabetes Association Releases Statement on Liver Disease in Diabetes." Accessed October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Symptoms & Causes of NAFLD & NASH." Accessed October 2026.
- NIDDK. "Diagnosis of NAFLD & NASH." Accessed October 2026.
- NIDDK. "Treatment for NAFLD & NASH." Accessed October 2026.
- NIH LiverTox. "Herbal and Dietary Supplements." NCBI Bookshelf, NBK548441. Accessed October 2026.
- MedlinePlus Medical Encyclopedia. "Cirrhosis." Accessed October 2026.
- NIDDK. "Treatment for Cirrhosis." Accessed October 2026.
Next Steps
Ask your primary care clinician or diabetes clinician whether liver-scarring risk has been assessed and what follow-up fits your history. Bring prior reports, a short description of any changes, and a complete medicine-and-supplement list. Agree on who will explain results and coordinate care. Seek emergency care for urgent warning signs rather than waiting for routine testing.
For adults with type 2 diabetes or prediabetes who want lifestyle education alongside clinical care, the Done With Diabetes™ program, a holistic approach to type 2 diabetes, offers ways to organize learning about daily habits such as meals, movement, sleep, and stress. It does not diagnose or treat liver disease, interpret lab results, change medicines, or substitute for your care team.